InMed Pharmaceuticals Inc.
INM
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.06% | -6.73% | -3.27% | 7.50% | -12.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.06% | -6.73% | -3.27% | 7.50% | -12.53% |
| Cost of Revenue | -7.05% | -33.34% | -38.13% | -38.51% | -34.54% |
| Gross Profit | -18.04% | -31.92% | -8.41% | 39.07% | -35.59% |
| SG&A Expenses | 9.01% | 10.14% | 18.29% | 21.58% | 20.41% |
| Depreciation & Amortization | -1.59% | -2.99% | -3.87% | -3.32% | -1.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.83% | -12.42% | -6.66% | -9.32% | -4.70% |
| Operating Income | -6.37% | -0.29% | -8.39% | 3.32% | -20.92% |
| Income Before Tax | -1.03% | 3.74% | -19.79% | -5.74% | -35.82% |
| Income Tax Expenses | -- | -- | -- | -- | 294.44% |
| Earnings from Continuing Operations | -0.94% | 3.83% | -19.67% | -5.64% | -35.90% |
| Earnings from Discontinued Operations | -223.93% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.38% | 3.15% | -20.46% | -6.34% | -36.79% |
| EBIT | -6.37% | -0.29% | -8.39% | 3.32% | -20.92% |
| EBITDA | -6.61% | -0.37% | -8.76% | 3.33% | -21.68% |
| EPS Basic | 76.62% | 70.78% | 48.60% | 64.31% | 49.85% |
| Normalized Basic EPS | 76.85% | 71.10% | 48.89% | 64.48% | 50.09% |
| EPS Diluted | 76.62% | 70.78% | 48.60% | 64.31% | 49.85% |
| Normalized Diluted EPS | 76.85% | 71.10% | 48.89% | 64.48% | 50.09% |
| Average Basic Shares Outstanding | 363.37% | 358.97% | 266.25% | 156.61% | 139.48% |
| Average Diluted Shares Outstanding | 363.37% | 358.97% | 266.25% | 156.61% | 139.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |